Infectious Disease Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia

This Phase 3 trial is exploring several treatments for people hospitalized with community-acquired pneumonia and COVID-19 who need intensive care. The goal is to find therapies that help patients survive and recover more quickly from these serious lung infections. Because the study is open to many patients worldwide, it may provide important new options for those facing severe respiratory illness.

The Study of Brave-LC LDN Treatment Trial

This Phase 3 study focuses on children and young adults with Long COVID, specifically looking at whether low-dose naltrexone can reduce the persistent fatigue many experience. If successful, this treatment could offer relief to young people struggling with ongoing tiredness after their initial COVID-19 infection. The trial is enrolling about 1,300 participants across the United States and will provide results after 16 weeks of treatment.

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations

This Phase 4 trial is testing new COVID-19 vaccines designed to protect against current variants of the virus. By improving the immune response, these updated vaccines might offer better protection for people exposed to SARS-CoV-2. The study is recruiting around 600 participants in the United States to assess safety and effectiveness.

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

This Phase 2 study is looking at whether the drug Fisetin can reduce inflammation and slow disease progression in adults hospitalized with COVID-19. Since excessive inflammation can worsen outcomes, finding an effective treatment could help patients recover more smoothly. The study is active but not currently enrolling and includes 80 participants at a single site in the United States.

Working Towards Empowered Community-driven Approaches to Increase Vaccination and Preventive Care Engagement

This study is testing a community-based program that uses mobile health tools and care coordination to boost COVID-19 vaccination rates among underserved groups. Increasing vaccine access and engagement with preventive care can help protect more people in communities that often face barriers to healthcare. The trial is enrolling nearly 400 participants in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.